5 active not recruiting, 5 completed, 4 terminated, 3 recruiting. 14 Phase 2, 6 Phase 1, 3 Phase 3, 1 Early Phase 1.
Follow 2C4 antibody: new trials by email Literature Review of 2C4 antibody trials Research Report on 2C4 antibody
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-09-24 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Paclitaxel, Trastuzumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 25 | 2022-04-20 | 2026-05-19 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Docetaxel, Lumpectomy, Mastectomy - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 2175 | 2020-03-13 | 2026-10-19 |
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration - Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Unknown | Academic and Community Cancer Research United | 480 | 2020-02-20 | 2023-12-18 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Colon Adenocarcinoma, ERBB2 Gene Amplification | Phase 2 | Completed | SWOG Cancer Research Network | 240 | 2017-11-27 | 2026-02-10 |
| Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-03-23 | 2026-07-30 |
| Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab - HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | City of Hope Medical Center | 18 | 2016-07-15 | 2025-11-14 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-22 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure - HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 315 | 2014-02-18 | 2026-10-06 |
| Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy HER-2/neu Intracellular Domain Protein, Laboratory Biomarker Analysis, Pertuzumab - HER2/Neu Positive, Recurrent Breast Carcinoma | Phase 1 / Phase 2 | Completed | University of Washington | 31 | 2014-02-05 | 2023-04-18 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation - HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 2 | Completed | City of Hope Medical Center | 63 | 2013-07-17 | 2026-06-16 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-10-01 | 2015-03-31 |
Breast Neoplasms (11) · Colonic Neoplasms (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Rectal Neoplasms (3) · Hematologic Neoplasms (2) · Inflammatory Breast Neoplasms (2) · Multiple Myeloma (2) · Ovarian Neoplasms (2) · Anemia (1) · Blast Crisis (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1)
National Cancer Institute (NCI) (6) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · SWOG Cancer Research Network (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · ECOG-ACRIN Cancer Research Group (1) · Jonsson Comprehensive Cancer Center (1)
United States (18) · Puerto Rico (4) · Canada (1) · Guam (1)
Charles E Geyer (1) · Joanne Mortimer (1) · Joanne Mortimer, MD (1) · Kanwal Raghav (1) · Keith T Flaherty (1) · Kimmie Ng (1) · Lara Davis (1) · Lara Davis, MD (1) · Lupe Salazar (1) · Mariya Rozenblit (1) · Mothaffar F Rimawi (1) · Nadine M Tung (1) · Nicholas P McAndrew (1) · Rachel Layman, MD (1) · Roisin M Connolly (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38433347, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39761503, PMID 39863139, PMID 39913886, PMID 40170372, PMID 40865033, PMID 41066729, PMID 41116969, PMID 42623567
U10CA180820 (3), U10CA180868 (2), U10CA180888 (2), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), R01CA166020 (1), U01CA062490 (1), U10CA012027 (1), U19AT006028 (1), U24CA196172 (1), UM1CA186688 (1)